Glaukos Corporation (NYSE:GKOS) ranks among the best medical device stocks to invest in. As Glaukos Corporation (NYSE:GKOS) nears the October 20 PDUFA date for its Epioxa medication, Stifel reaffirmed its Buy rating and $115 price target for the company on October 8. According to the firm’s survey of 27 corneal cross-linking (CXL) ophthalmologists, Epioxa’s uptake and volume projections seem to be robust. wavebreakmedia/Shutterstock.com The survey’s findings confirm Stifel’s prediction that the medicati ...